NASDAQ : ANAB
AnaptysBio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 48.28 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.44B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.44B |
| Enterprise Value | 1.55B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 29.90M |
| Shares Outstanding | 29.90M |
| Shares Change (YoY) | +26.17% |
| Shares Change (QoQ) | +25.39% |
| Owned by Insiders (%) | 2.33% |
| Owned by Institutions (%) | 79.62% |
| Float | 20.50M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 6.90 |
| Forward PE | 17.19 |
| PS Ratio | 13.61 |
| Forward PS | 11.05 |
| PB Ratio | 135.59 |
| P/TBV Ratio | 136.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 5.91 |
| EV / Sales | 14.60 |
| EV / EBITDA | 23.57 |
| EV / EBIT | 23.58 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.61 |
| Quick Ratio | 5.54 |
| Debt / Equity | 25.47 |
| Debt / EBITDA | 4.10 |
| Debt / FCF | n/a |
| Interest Coverage | 0.80 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 56.62% |
| Return on Capital Employed (ROCE) | 23.33% |
| Weighted Average Cost of Capital (WACC) | 9.47% |
| Revenue Per Employee | $1.02M |
| Profits Per Employee | $2.52M |
| Employee Count | 104 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -362.90M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +33.67% |
| 50-Day Moving Average | 51.76 |
| 200-Day Moving Average | 56.49 |
| Relative Strength Index (RSI) | 46.74 |
| Average Volume (20 Days) | 495,441 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.39M |
| Short Previous Month | 5.24M |
| Short % of Shares Out | 18.04% |
| Short % of Float | 26.31% |
| Short Ratio (days to cover) | 9.41 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 106.09M |
| Gross Profit | 111.42M |
| Operating Income | 65.70M |
| Pretax Income | -10.19M |
| Net Income | 261.99M |
| EBITDA | 65.71M |
| EBIT | 65.70M |
| Earnings Per Share (EPS) | $7.00 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 164.14M |
| Total Debt | 269.59M |
| Net Cash | -105.45M |
| Net Cash Per Share | -$3.53 |
| Equity (Book Value) | 10.59M |
| Book Value Per Share | 0.36 |
| Working Capital | 163.07M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -105.12M |
| Capital Expenditures | -69,000 |
| Depreciation & Amortization | 18,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -105.12M |
| FCF Per Share | -$3.52 |
Margins
| Measure | Value |
|---|
| Gross Margin | 105.03% |
| Operating Margin | 61.93% |
| Pretax Margin | -9.60% |
| Profit Margin | 246.96% |
| EBITDA Margin | 61.94% |
| EBIT Margin | 61.93% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.17% |
| Shareholder Yield | -26.17% |
| Earnings Yield | 14.50% |
| FCF Yield | -7.28% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $87.25 |
| Price Target Difference | 80.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 38.70% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.24 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |